The revealing word in Rhia Ventures’ new financing plan is “sustaining.” In venture capital, the familiar story moves from seed money to growth to an exit. Rhia has added a place for enterprises that need flexible support simply to keep delivering care. A birth center can matter enormously to its community without becoming the next spectacular acquisition. What kind of investor has room for that?
- Incubate investment in overlooked women’s health businesses.
- Help investors examine who benefits from their money.
- Develop financing that fits community-led care.
Rhia is a nonprofit working where reproductive health meets financial decision-making. Its audience includes foundations, investors, employers and entrepreneurs. Its intended beneficiaries are people poorly served by the American health market, particularly communities facing racial and economic barriers. That distance between the person writing the check and the person needing care is the territory Rhia occupies.
The fund that left home
Founded in 2018, Rhia helped build an unusual arrangement: a nonprofit with a wholly owned investment subsidiary, RH Capital. Co-founder and board chair Ruth Shaber brought the perspective of a physician and the backing of Tara Health Foundation. The arrangement gave women’s health innovation a financial home when specialist investment in the field was less established.
By September 2024, Rhia reported that RH Capital’s two funds had reached $43.5 million in combined assets under management and backed more than 20 companies. Those figures describe investment funds, not Rhia’s revenue or a startup financing round. The distinction matters. Money committed to investments does a different job from money paying for a nonprofit’s operations.
Combined assets under management across Funds I and II.
Then the investment team moved out. Elizabeth Bailey, Stasia Obremskey and Alice Zheng launched Foreground Capital, with the transition effective October 1, 2024. Foreground continued managing the legacy funds. Rhia presented the change as evidence that the women’s health market had matured enough to support an independent firm.
That is a more interesting milestone than another fund announcement. An organization built to encourage a market had helped produce a team able to operate independently within it. Rhia’s remaining question was which needs conventional venture capital would still struggle to finance.
Some care needs a different contract
The clearest answer is Lifecycle Capital. Its July 2026 fact sheet describes an initial $15 million fundraising target: $10 million in repayable capital and $5 million in grants. A larger strategy targets $50 million-plus. These are plans, not announced closes. The first phase pairs enterprise financing with support for infrastructure and technical assistance.
The target market includes doula collectives, midwifery practices, birth centers and early-stage health solutions. Rhia organizes support around seeding, scaling and sustaining, with instruments including concessionary debt, revenue-based financing and recoverable grants. The premise is practical: enterprises serving vulnerable populations may have thin margins or uneven cash flow. Their financing needs to accommodate that reality.
This is where Rhia differs from a specialist venture investor alone. It can work on the terms of capital, the practices of investors and the surrounding market. Its nonprofit model includes philanthropic support; a Catalytic Capital Consortium project, for example, provided a $130,000 grant for equity-centered investment framework development.
Give the good intention a paper trail
Rhia also makes tools for people already moving money. HEART, the Health Equity Assessment and Rating Tool, turns a broad aspiration into questions about organizational practice. Adapted from the Racial Equity Assessment Lab framework, it includes investor assessments and a diligence tool for early- to growth-stage health companies with some pilot data.
Its ratings move through four levels, from Equity-Blind to Equity-Focused. The useful wrinkle is the demand for evidence. An organization may believe it chooses diverse partners, but a written policy makes that practice inspectable. The framework asks investors to examine what they do, what they document and whose experience informs the decision.
There is a straightforward lesson to copy: put the equity question into diligence before approving an investment, then decide what evidence would show progress. A score cannot establish that patients are healthier. It can make an investor’s reasoning visible and create a basis for follow-up.
Training makes that approach concrete. In May 2025, Rhia announced a six-month impact-management cohort with Impact Frontiers and Duke University’s CASE. The published price was $15,000 per organization for up to five participants, with scholarships available. Participants would develop rating models, apply HEART and receive two consulting sessions. That is an actual service with a stated price and a defined audience.
The shareholder meeting is a health venue
Rhia’s corporate engagement work uses another route: investors in public companies. It coordinates dialogue and shareholder proposals about reproductive health benefits and the relationship between corporate commitments and political spending. Its benefits database gives employees and investors a starting point for questions about travel coverage, paid time off and other disclosed support.
The database is deliberately bounded by publicly disclosed, reported or authorized information. A blank entry cannot settle what an employee’s plan covers. Likewise, submitting a shareholder proposal is an action, not proof of a policy victory. These distinctions keep useful pressure from turning into inflated claims.
“I came to Rhia because I was curious about how decision-making changes when a nonprofit effectively owns a venture fund.”Erika Seth Davies · Tara Health Foundation conversation
Davies has also described the Community Advisory Council as a source of opportunity and accountability. That adds a necessary complication: people affected by investment decisions can challenge the organization’s assumptions. For founders, Rhia offers a way to examine financing fit. For allocators, it offers a way to question the process behind a portfolio. Both depend on willingness to change decisions when the answers are uncomfortable.